SCHEMBL23936998

SCHEMBL23936998

CN(C/C=C/C(N)=O)CCOC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23394209 0.85
SCHEMBL25844821 0.83 PIK3CD (0.37)
SCHEMBL21569008 0.83 PIK3CD (0.37)
SCHEMBL16653813 0.77 MAPT (0.32)
SCHEMBL8169148 0.72
SCHEMBL22240475 0.72
SCHEMBL31143647 0.72 PYCR1 (0.38)
SCHEMBL23173313 0.70 KDM4A (0.31)
SCHEMBL1458708 0.69
SCHEMBL2535305 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3922630-A1 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER Capella Therapeutics, Inc. (US) 2021-12-15 EP disclosed
EP-3119762-B9 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER CAPELLA THERAPEUTICS INC (US) 2021-10-20 EP disclosed